Baxter International Stock Performance and Analyst Ratings
Baxter International Inc. (BAX) reported strong Q2 FY2026 earnings, with shares rising 8.1% after the company exceeded revenue and EPS guidance. The firm's global sales increased by 5%, driven primarily by growth in Infusion Therapies & Platforms and Advanced Surgery segments. Baxter also raised its full-year outlook for both organic and reported sales as well as adjusted EPS guidance. Despite a year-to-date gain of 40%—outperforming the S&P 500's 8.7% rise—the stock has underperformed over the past year, declining by 4.6%. Analysts remain cautious with a consensus rating of 'Hold' based on two 'Strong Buy', 11 'Hold', and two 'Strong Sell' ratings. The company is leveraging its Baxter Growth and Performance System (GPS) to stabilize operations and strengthen financial performance.
Tickers: $BAX